MedWatch

MSD fined for employee’s LinkedIn post

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

If you are employed in the pharmaceutical industry, you should think twice before sharing something on social media platforms like Facebook and LinkedIn.

An employee in MSD’s Danish department learned that the hard way after an anonymous person reported a LinkedIn post concerning the EU approval of the drug Keytruda (pembrolizumab) for treatment of Hodgkin's lymphoma to The Ethical Committee for the Pharmaceutical Industry (ENLI).

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier